Tandem cycle high-dose chemotherapy (HDCT) of melphalan (MEL) and busulfan/cyclophosphamide (BU/CY) with peripheral blood progenitor cell rescue (PBPC) in multiple myeloma (MM).

被引：0
|
作者：
Somlo, G [1 ]
Snyder, D [1 ]
Brown, A [1 ]
Dagis, A [1 ]
Nademanee, A [1 ]
ODonnell, M [1 ]
Parker, P [1 ]
Stein, A [1 ]
Smith, E [1 ]
Molina, A [1 ]
Spielberger, R [1 ]
Margolin, K [1 ]
Planas, I [1 ]
Kashyap, A [1 ]
Chow, W [1 ]
Fung, H [1 ]
Bhatia, R [1 ]
Forman, SJ [1 ]
机构：
[1] CITY HOPE NATL MED CTR,DUARTE,CA 91010
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1709 / 1709
页数：1
相关论文
共 50 条
  • [1] Survival and toxicity update following tandem cycle high-dose melphalan (MEL) and busulfan/cyclophosphamide (Bu/Cy) with autologous peripheral blood progenitor cell rescue (PBPC) in multiple myeloma (MM); Lack of correlation between the incidence of hepatic venoocclusive disease (VOD) and busulfan pharmacokinetics.
    Somlo, G
    Parker, P
    Stein, A
    Rodriguez, R
    Spielberger, R
    Molina, A
    Kashyap, A
    Fung, H
    Nademanee, A
    O'Donnell, M
    Krishnan, A
    Margolin, K
    Chow, W
    Synold, T
    Schriber, J
    Alvarnas, J
    Ward, K
    Sniecinski, I
    Longmate, J
    Forman, SJ
    BLOOD, 1998, 92 (10) : 373B - 373B
  • [2] High-dose therapy with peripheral blood progenitor cell (PBPC) autografting in multiple myeloma (MM)
    Goldschmidt, H
    Hegenbart, U
    Wallmeier, M
    Fruehauf, S
    Hohaus, S
    Wannenmacher, M
    Haas, R
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 404 - 404
  • [3] Total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC) following high-dose melphalan (Mel) and PBPC as part of tandem autologous transplant (TAT) for patients with multiple myeloma.
    Somlo, George
    Liu, An
    Schultheiss, Timothy E.
    Frankel, Paul Henry
    Spielberger, Ricardo Tomas
    Popplewell, Leslie
    Zhou, Kenny
    Hawkins, Donna
    Krishnan, Amrita Y.
    Sahebi, Firoozeh
    Parker, Pablo Miguel
    Forman, Stephen J.
    Wong, Jeffrey Y. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Collection of peripheral blood progenitor cells (PBPC) in patients with multiple myeloma (MM) after high-dose cyclophosphamide (HDCYC).
    Mant, G
    Thiessard, F
    Faberes, C
    ConyMakhoul, P
    Boiron, JM
    Pigneux, A
    Vezon, G
    Bernard, P
    Broustet, A
    Salmi, R
    Reiffers, J
    BLOOD, 1996, 88 (10) : 3681 - 3681
  • [5] Total marrow irradiation and peripheral blood progenitor cell rescue following high-dose melphalan and peripheral blood progenitor cell rescue in patients with multiple myeloma
    Somlo, G
    Forman, S
    Popplewell, L
    Spielberger, R
    Sahebi, F
    Parker, P
    Schultheiss, T
    Liu, A
    Krishnan, A
    Wong, J
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 120 - 121
  • [6] Phase I trial of escalating doses of total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC), following high-dose melphalan and PBPC as part of tandem high-dose therapy (THDT) for patients with multiple myeloma (MM)
    Somlo, G.
    Forman, S.
    Popplewell, L.
    Parker, P.
    Schultheiss, T.
    Wong, J.
    Frankel, P.
    Spielberger, R.
    Sahebi, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 193 - 193
  • [7] Phase I trial of escalating doses of total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC) following high-dose melphalan and PBPC as part of tandem high-dose therapy (THDT) for patients with multiple myeloma (MM)
    Wong, J. Y.
    Somlo, G.
    Spielberger, R.
    Forman, S.
    Poppelwell, L.
    Schultheiss, T.
    Frankel, P.
    Krishnan, A.
    Sahebi, F.
    Parker, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Tandem cycle high-dose melphalan and intravenous busulfan/cytoxan with peripheral blood progenitor cell rescue (PBPC) followed by interferon α-2 (IF) with, or without thalidomide (Thal) for multiple myeloma.: High complete response rate and moderate toxicities.
    Somlo, G
    Yamamoto, N
    Sarah, C
    O'Donnell, M
    Snyder, D
    Sahebi, F
    Kogut, N
    Spielberger, R
    Molina, A
    Parker, P
    Popplewell, L
    Fung, H
    Rodriguez, R
    Stein, A
    Krishnan, A
    Chow, W
    Lopez, F
    Forman, S
    BLOOD, 2001, 98 (11) : 685A - 685A
  • [9] HIGH-DOSE BUSULFAN (BU), VP-16, CYTOXAN (CY) WITH MARROW RESCUE (BMT) FOR MULTIPLE-MYELOMA (MM)
    SEAY, TE
    DEVINE, SM
    GELLER, RT
    HEFFNER, LT
    HILLYER, C
    HOLLAND, HK
    RODEY, GE
    SARAL, R
    VOGLER, WR
    WINTON, EF
    DIX, SP
    PASCUZZI, CC
    YORK, RC
    WINGARD, JR
    BLOOD, 1993, 82 (10) : A578 - A578
  • [10] High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)
    Rodriguez, Tulio E.
    Stiff, Patrick J.
    Smith, Scott E.
    Kaufman, Jonathan L.
    Lee, Mary
    Parthasarathy, Mala
    Earley, Zachary M.
    Lonial, Sagar
    Vesole, David H.
    BLOOD, 2010, 116 (21) : 582 - 582
12345